Patents Examined by Anish Gupta
  • Patent number: 8207172
    Abstract: The invention relates to novel heterocycles of formula (I) processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: June 26, 2012
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Chengzhi Zhang, Jacques Dumas, Qingming Zhu, Roger Smith, Qingjie Liu, Sharad Verma, Jason Duquette, Qian Zhao, Dongping Fan, Georgiy Bondar, Philip Coish
  • Patent number: 8207295
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: June 26, 2012
    Assignee: Synergy Pharmaceuticals, Inc.
    Inventors: Kunwar Shailubhai, Gary S. Jacob
  • Patent number: 8202841
    Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: June 19, 2012
    Assignee: MannKind Corporation
    Inventors: Liping Liu, Zhidong Xie, David C. Diamond
  • Patent number: 8198310
    Abstract: Use of a compound of formula (I) in which R, R? and R? have the meanings given in the description, optionally in the form of a salt thereof with a pharmaceutically acceptable organic or mineral base, to prepare a pharmaceutical composition for reducing the blood triglyceride, cholesterol and glucose levels.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: June 12, 2012
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.S.p.A.
    Inventors: Angelo Guglielmotti, Giuseppe Biondi
  • Patent number: 8198247
    Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: June 12, 2012
    Assignee: Telik, Inc.
    Inventors: William A. Boulanger, Dennis L. Edie, Ronan Y. Guevel, Pedro E. Hernandez Abad, R. Jason Herr, Harold Meckler, Steven R. Schow, Pavel E. Zhichkin
  • Patent number: 8198406
    Abstract: The present invention relates to methods and compositions for modulating angiogenesis. In particular, the present invention relates to Pigment Epithelial-derived Factor (PEDF) fragments for use in modulating angiogenesis and treating angiogenesis mediated disease.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: June 12, 2012
    Assignee: Northwestern University
    Inventors: Olga Volpert, Yelena Mirochnik
  • Patent number: 8187612
    Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of botulinum toxin types A, B, C, D, E, F and G.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: May 29, 2012
    Assignee: Allergan, Inc.
    Inventors: Kei Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
  • Patent number: 8183343
    Abstract: A therapeutic method for treating a skin wound involving administering to a patient in need thereof a composition containing pharmaceutically effective amounts of the following components: (1) a peptide consisting of the amino acid sequence represented by Ser-Ser-Ser-Arg (SEQ ID NO: 1) or pharmaceutically acceptable salts thereof and (2) a peptide consisting of the amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (SEQ ID NO: 2) or substance P or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable additive.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: May 22, 2012
    Assignees: Santen Pharmaceutical Co., Ltd.
    Inventors: Teruo Nishida, Makoto Inui, Masatsugu Nakamura
  • Patent number: 8183341
    Abstract: This invention relates to a novel antibiotic compounds, pharmaceutically acceptable salts and derivatives thereof, and to methods for obtaining such compounds.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: May 22, 2012
    Assignee: Novartis AG
    Inventors: Matthew J. Lamarche, Jennifer A. Leeds, Phillipp Krastel, Hans-Ulrich Naegeli
  • Patent number: 8163874
    Abstract: Disclosed is a method of making peptide structures that are stable in aqueous and non-aqueous media where a first linear peptide chain comprising alternating D,L- or L,D-amino acids having an N and C termini is joined by at least one turn region to a second linear peptide chain comprising alternating D,L- or L,D-amino acids having an N and C termini. The peptide chains can be joined at the C terminus of one of the linear peptide chains with an N terminus of the other linear peptide chain, a C terminus of one of the linear peptide chains with a C terminus of the other linear peptide chain, or an N terminus of one of the linear peptide chains with an N terminus of the other linear peptide chain.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: April 24, 2012
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: John L Kulp, Thomas D Clark
  • Patent number: 8148375
    Abstract: The invention relates to (cyclopropylphenyl) phenyloxamides and their physiologically tolerated salts, and their use as a medicament.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: April 3, 2012
    Assignee: Sanofi-Aventis
    Inventors: Elisabeth Defossa, Thomas Klabunde, Viktoria Dietrich, Siegfried Stengelin, Guido Haschke, Andreas Herling, Johanna Kuhlmann-Gottke, Stefan Bartoschek
  • Patent number: 8148322
    Abstract: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: April 3, 2012
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Hazel Szeto, Kesheng Zhao, Hugh Robertson, Alex Birk
  • Patent number: 8129333
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: March 6, 2012
    Assignee: Immune Targeting Systems Ltd.
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
  • Patent number: 8129330
    Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: March 6, 2012
    Assignee: Mountain View Pharmaceuticals, Inc.
    Inventors: Alexa L Martinez, Merry R Sherman, Mark G. P. Saifer, L. David Williams
  • Patent number: 8129332
    Abstract: The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: March 6, 2012
    Assignee: Arizona Board of Regents
    Inventors: Colleen Brophy, Alyssa Panitch, Padmini Komalavilas, Brandon Seal, Lokesh Joshi
  • Patent number: 8129331
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: March 6, 2012
    Assignee: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Patent number: 8124579
    Abstract: The present invention provides novel HSP20-based polypeptides and pharmaceutical compositions thereof, and methods for using such polypeptides and pharmaceutical compositions for various therapeutic uses.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: February 28, 2012
    Assignee: Arizona Board of Regents
    Inventors: Colleen Brophy, Elizabeth Furnish, Padmini Komalavilas, Catherin Dreiza, Alyssa Panitch
  • Patent number: 8110540
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: February 7, 2012
    Assignee: Immune Targeting Systems Ltd.
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
  • Patent number: 8110541
    Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: February 7, 2012
    Assignee: Immune Targeting Systems Ltd.
    Inventors: Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
  • Patent number: 8101570
    Abstract: A heparin-binding growth factor (HBGF) analog having two substantially similar sequences (homodimeric sequences) branched from a single amino acid residue, where the sequences are analogs of a particular HBGF that binds to a heparin-binding growth factor receptor (HBGFR), or alternatively that bind to a HBGFR without being an analog of any particular HBGF. The homodimeric sequences may be derived from any portion of a HBGF. The synthetic HBGF analog may be an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any HBGFR. Further provided are preparations for medical devices, pharmaceutical compositions and methods of using the same.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: January 24, 2012
    Assignee: BioSurface Engineering Technologies, Inc.
    Inventors: Kazuyuki Takahashi, Paul O. Zamora, Louis A. Pena, Xinhua Lin